Structural studies of the MHC class I peptide loading complex
MHC I 类肽装载复合物的结构研究
基本信息
- 批准号:7873965
- 负责人:
- 金额:$ 20.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntigen PresentationAntigensArchitectureBindingCD8B1 geneCell surfaceCellsComplexERp57Electron MicroscopyEndoplasmic ReticulumGoalsHistocompatibility Antigens Class IHumanImmune responseImmune systemIndividualInsectaLectinMHC Class I GenesMethodsModelingModificationMolecularMolecular ChaperonesMolecular ConformationOncogenic VirusesPeptidesPlayProcessProtein Disulfide IsomeraseProteinsQuality ControlResolutionRoentgen RaysRoleSite-Directed MutagenesisStructureT-LymphocyteTechniquesTestingUrsidae FamilyX-Ray Crystallographyantigenic peptide transportercalreticulinmilligramparticleprotein foldingpublic health relevancereconstitutionresponsescale uptapasin
项目摘要
DESCRIPTION (provided by applicant): In a process central to the immune response against viruses and tumors, MHC class I molecules present peptide antigens at the cell surface for recognition by CD8+ T cells. MHC class I molecules are loaded with peptide in the endoplasmic reticulum (ER) while sequestered within the peptide loading complex, or PLC. The PLC consists of the Transporter associated with Antigen Processing (TAP), which translocates antigenic peptides into the ER, and an ER-luminal subcomplex. This luminal subcomplex is sufficient for peptide loading as well as for the exchange of low affinity for high affinity peptides, or "peptide editing". In addition to the MHC class I molecule, the subcomplex comprises the lectin chaperone calreticulin, the protein disulfide isomerase ERp57, and tapasin, an MHC class I specific chaperone. How the components of luminal PLC subcomplex cooperate to facilitate peptide loading and editing has been difficult to understand in the absence of a structure for the whole subcomplex. Here we propose to obtain this critical structural information for the entire ER-luminal PLC subcomplex as a means to understanding the molecular mechanisms underlying its function. The first aim is to obtain sufficient material for structure determination. At present, we are able to reconstitute the complex from components in quantities sufficient for single particle electron microscopy (EM), and our challenge is to scale up for crystallographic studies. We are also developing a second approach, where the components of the luminal subcomplex are assembled in insect or human lymphoblastoid cells and the entire subcomplex is then isolated. The second aim is to determine the structure of the ER-luminal PLC subcomplex, either by X-ray crystallography or by EM. Low resolution information from EM will show how tapasin, ERp57, and calreticulin are arranged around the MHC class I molecule, thereby providing clues as to their function in the loading process. An X-ray structure will reveal details regarding how these proteins interact with the MHC class I peptide binding groove and would thus suggest the mechanism by which the PLC facilitates peptide loading and exchange. An understanding of PLC architecture is relevant not only for MHC class I maturation but also more generally for understanding protein folding and quality control in the ER, since ERp57 and calreticulin are general foldases that are not restricted to the MHC class I molecule.
PUBLIC HEALTH RELEVANCE: MHC class I molecules present peptide antigens at the cell surface for recognition by the immune system, playing a critical role in the response against viruses and tumors. The class I molecules are loaded with antigenic peptides by the peptide loading complex. We propose to visualize this complex in order to understand the molecular mechanisms by which peptide loading takes place.
描述(由申请人提供):在针对病毒和肿瘤的免疫反应的核心过程中,MHC I类分子在细胞表面呈现肽抗原,供CD8+ T细胞识别。MHC I类分子在内质网(ER)中装载肽,同时被隔离在肽装载复合体(PLC)中。PLC由与抗原加工相关的转运蛋白(TAP)组成,它将抗原肽转运到内质网,以及内质网腔亚复合物。这种腔内亚复合物对于肽装载以及低亲和力与高亲和力肽的交换或“肽编辑”是足够的。除了MHC I类分子外,该亚复合物还包括凝集素伴侣钙网蛋白、蛋白二硫异构酶ERp57和tapasin (MHC I类特异性伴侣)。在缺乏整个亚复合物的结构的情况下,很难理解管腔PLC亚复合物的成分如何合作以促进肽的装载和编辑。在这里,我们建议获得整个ER-luminal PLC亚复合物的关键结构信息,作为理解其功能背后的分子机制的手段。第一个目标是获得足够的材料来确定结构。目前,我们能够从足够数量的单粒子电子显微镜(EM)中重建复合物,我们的挑战是扩大晶体学研究的规模。我们还在开发第二种方法,将管腔亚复合物的成分组装在昆虫或人类淋巴母细胞样细胞中,然后分离整个亚复合物。第二个目标是通过x射线晶体学或EM来确定ER-luminal PLC亚复合物的结构。EM的低分辨率信息将显示tapasin, ERp57和calreticulin如何排列在MHC I类分子周围,从而为它们在加载过程中的功能提供线索。x射线结构将揭示这些蛋白质如何与MHC I类肽结合槽相互作用的细节,从而提示PLC促进肽装载和交换的机制。了解PLC结构不仅与MHC I类成熟有关,而且更普遍地与理解内质网中的蛋白质折叠和质量控制有关,因为ERp57和钙网蛋白是不局限于MHC I类分子的一般折叠酶。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KARIN M REINISCH其他文献
KARIN M REINISCH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KARIN M REINISCH', 18)}}的其他基金
Pathophysiology of Plasma Membrane PI4P Generation
质膜 PI4P 生成的病理生理学
- 批准号:
9278254 - 财政年份:2015
- 资助金额:
$ 20.69万 - 项目类别:
Pathophysiology of Plasma Membrane PI4P Generation
质膜 PI4P 生成的病理生理学
- 批准号:
9069989 - 财政年份:2015
- 资助金额:
$ 20.69万 - 项目类别:
SNARE PRE-FUSION INTERMEDIATE WITH INHIBITORY PEPTIDES
含有抑制肽的 SNARE 预融合中间体
- 批准号:
8170615 - 财政年份:2010
- 资助金额:
$ 20.69万 - 项目类别:
Structural studies of the MHC class I peptide loading complex
MHC I 类肽装载复合物的结构研究
- 批准号:
8066717 - 财政年份:2010
- 资助金额:
$ 20.69万 - 项目类别:
STRUCTURAL STUDIES OF THE TRAPP MEMBRANE TETHERING COMPLEX
TRAPP 膜束缚复合物的结构研究
- 批准号:
7955207 - 财政年份:2009
- 资助金额:
$ 20.69万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 20.69万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 20.69万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 20.69万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 20.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 20.69万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 20.69万 - 项目类别: